Linked Life Data

15140404

Source:http://linkedlifedata.com/resource/pubmed/id/15140404

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-5-13
pubmed:abstractText
Tumor vasculature is an attractive therapeutic target as it differs structurally from normal vasculature, and the destruction of a single vessel can lead to the death of many tumor cells. The effects of antivascular drugs are frequently short term, with regrowth beginning less than 24 hours posttreatment. This study investigated the duration of the response to the vascular targeting agent, ZD6126, of the GH3 prolactinoma, in which efficacy and dose-response have previously been demonstrated. GH3 prolactinomas were grown in the flanks of eight Wistar Furth rats. All animals were treated with 50 mg/kg ZD6126. The tumors were examined with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 24 hours pretreatment and posttreatment, and at a single time between 48 and 96 hours posttreatment. No evidence of recovery of perfusion was observed even at the longest (96-hour) time point. Involvement of a statistician at the project planning stage and the use of DCE-MRI, which permits noninvasive quantitation of parameters related to blood flow in intact animals, allowed this highly significant result to be obtained using only eight rats.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-10508284, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-10778982, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-10974632, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-11413510, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12007956, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12060643, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12097279, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12239609, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12438217, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12499266, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12771928, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12807936, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-12832588, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-2895486, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-7217831, http://linkedlifedata.com/resource/pubmed/commentcorrection/15140404-7584949
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1522-8002
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
150-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:articleTitle
Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.
pubmed:affiliation
Department of Basic Medical Sciences, St. George's Hospital Medical School, Tooting, London, UK. d.mcintyre@sghms.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't